Free crystal form and hydrochloride crystal form of a casein lyase agonist, their preparation methods and applications
By preparing the free and hydrochloride crystal forms of casein lyase agonists, the problems of stability and industrial production of casein lyase agonists have been solved, and a stable crystal form suitable for drug development has been achieved, which is applicable to the prevention and treatment of related diseases.
Patent Information
- Application Number
- CN202611287777.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-24
- Publication Date
- 2026-11-17
AI Technical Summary
The crystal forms of existing casein lyase agonists vary significantly in terms of stability, hygroscopicity, solubility, formulation dissolution rate, and industrial production, making it difficult to meet the needs of drug development.
This invention provides methods for preparing the free and hydrochloride crystal forms of casein lyase agonists. Through specific chemical reactions and crystal structure control, a well-defined and reproducible crystal structure with good comprehensive physicochemical properties is obtained.
The prepared crystal form has a stable crystal structure, low hygroscopicity, and good solid-state stability, making it suitable for drug development and industrial production, and for the prevention and treatment of diseases mediated by HsClpP.
Smart Images

Figure CN123106674A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, specifically to the free crystal form and hydrochloride crystal form of a casein lyase agonist, as well as its preparation method and application. Background Technology
[0002] Human caseinolytic protease P (HsClpP) is a serine protease located in the mitochondrial matrix and is an important component of the mitochondrial protein quality control system. Its main function is to degrade misfolded, damaged, or abnormally aggregated mitochondrial proteins to maintain mitochondrial protein homeostasis and normal energy metabolism. Recent studies have shown that abnormal function or imbalanced expression of HsClpP is closely related to the development of various diseases, including tumors, autoimmune diseases, and metabolic diseases. The crystal forms of solid drugs can vary significantly in terms of stability, hygroscopicity, solubility, formulation dissolution rate, preparability, and industrial production. Therefore, obtaining a stable crystal form of a caseinolytic protease agonist with a well-defined crystal structure, stable preparation capability, and good overall solid-state properties is of great significance for the drug development of this type of compound. Summary of the Invention
[0003] To address the aforementioned shortcomings of existing technologies, the present invention aims to provide a free crystal form and a hydrochloride crystal form of a casein lyase agonist, as well as their preparation methods and applications. These crystal forms possess well-defined and reproducible crystal structures and exhibit excellent comprehensive physicochemical properties, meeting the needs of drug development and industrial production.
[0004] The technical solution of the present invention to solve the above-mentioned technical problems is as follows: A free crystal form A of a casein lyase agonist is provided, the chemical structural formula of which is shown in formula (Ⅲ):
[0005] (III) The free-state crystalline form A exhibits characteristic diffraction peaks at 2θ values of 6.8°±0.2°, 11.9°±0.2°, 12.1°±0.2°, 14.1°±0.2°, 15.5°±0.2°, 17.9°±0.2°, 19.4°±0.2°, 20.4°±0.2°, 21.5°±0.2°, 22.3°±0.2°, 23.7°±0.2°, 26.9°±0.2°, and 27.9°±0.2°.
[0006] This invention provides a method for preparing the above-mentioned free crystalline form A, comprising the following steps: adding Me3N·SO3 and triethylamine sequentially to a mixed solution of compound (II) and anhydrous acetonitrile, stirring at 60-70°C for 15-20 hours, filtering at 0-10°C, concentrating the filtrate, and then adding anhydrous ethanol to slurry to obtain an intermediate solid; dissolving the obtained intermediate solid in an aqueous sodium hydroxide solution and adding methanol until the system is completely dissolved; then adding hydrochloric acid dropwise under stirring to adjust the pH to 4-7, allowing it to stand and crystallize, adding dichloromethane to disperse the slurry, filtering, and drying the obtained solid to obtain the free crystalline form; The equivalent range of Me3N·SO3 is 6-8, the equivalent range of triethylamine is 10-12, and the equivalent range of sodium hydroxide is 3-5; the structural formula of compound (II) is as follows:
[0007] (II).
[0008] This invention provides a hydrochloride crystal form A of a casein lyase agonist, the chemical composition of which is C. 23 H 23 FN4O5S·HCl·H2O, the structural formula is shown in formula (Ⅰ):
[0009] (I) The hydrochloride crystal form A exhibits characteristic diffraction peaks at 2θ values of 6.2°±0.2°, 7.3°±0.2°, 11.3°±0.2°, 12.2°±0.2°, 13.3°±0.2°, 16.0°±0.2°, 16.7°±0.2°, 20.1°±0.2°, 22.6°±0.2°, 24.5°±0.2°, 25.0°±0.2°, 25.7°±0.2°, and 30.2°±0.2°.
[0010] This invention provides a method for preparing the above-mentioned hydrochloride crystal form A, comprising the following steps: (1) Prepare crystal seed of compound (I) using the above-mentioned free crystal form A; (2) Add the free crystal form A of formula (Ⅲ) to the mixed solvent and stir at 40-60℃ to form a suspension; (3) Add hydrochloric acid solution and crystal seed of compound (I) obtained in step (1) to the suspension in step (2), and then stir at 40-60°C for 1.5-2.5 hours. Then cool to 20-30°C and stir at this temperature until crystals precipitate. (4) The product obtained in step (3) is filtered, centrifuged and the solid is collected. The solid is then dried to obtain the final product. Furthermore, the specific process of step (1) is as follows: S1. Add the above-mentioned free crystal form A to a mixed solvent of acetonitrile and water, and stir at 40-60℃ to form a suspension; S2. Add hydrochloric acid solution to the suspension in step S1, then stir at 40-60°C for 1.5-2.5 hours, then cool to 20-30°C and stir at this temperature until crystals precipitate. S3. Filter the product obtained in step S2, centrifuge and collect the solid, and dry the obtained solid to obtain the final product.
[0011] Furthermore, in step S1, the volume ratio of acetonitrile to water is 88-92:8-12.
[0012] Furthermore, in step (2), the mixed solvent is a mixture of organic solvent and water; the volume ratio of organic solvent to water is 88-92:8-12; and the organic solvent is acetonitrile.
[0013] Furthermore, in step (3), the amount of hydrochloric acid solution added is 1.00-3.00 equivalents of the above-mentioned free crystal form A molar amount.
[0014] The present invention provides the use of the above-described free crystal form A or the above-described hydrochloride crystal form A in the preparation of a medicament for the prevention and / or treatment of diseases mediated by HsClpP.
[0015] Furthermore, diseases mediated by HsClpP include autoimmune diseases, neurological diseases, metabolic syndromes, and tumors.
[0016] The present invention provides a medicament for the prevention and / or treatment of diseases mediated by HsClpP, comprising the above-described free crystal form A and / or the above-described hydrochloride crystal form A.
[0017] Furthermore, the drug is an oral preparation; the dosage form of the drug is tablets, pills, sprays, solutions, suspensions, capsules, or granules.
[0018] The present invention has the following beneficial effects: The free crystal form A and the crystal form A of compound (I) provided by the present invention have a clear and stable crystal structure, can be prepared stably and repeatedly, and have good crystallinity, solid-state stability and low hygroscopicity. The free crystal form A and the crystal form A of compound (I) are stable monohydrates with a clear stoichiometric relationship and a stable hydration state, and can maintain good crystal form stability during storage and processing. At the same time, the free crystal form A and the crystal form A of compound (I) have good comprehensive physicochemical properties, making them suitable as pharmaceutical solid forms of compound (II), providing a reliable material basis for its formulation development and industrial production. Attached Figure Description
[0019] Figure 1 XRPD pattern of crystal form A of compound of formula (I) prepared in Example 2; Figure 2 The DSC curve of crystal form A of compound of formula (I) prepared in Example 2; Figure 3 TGA curve of crystal form A of compound of formula (I) prepared in Example 2; Figure 4 The ¹H-NMR spectrum of crystal form A of compound of formula (I) prepared in Example 2; Figure 5 XRPD spectra of compound (I) crystal form A prepared in Example 2 after treatment under different temperature and humidity conditions; Figure 6 XRPD spectra of compound (I) crystal form A prepared in Example 2 before and after DVS testing; Figure 7 The XRPD pattern of free crystal form A prepared in Example 1; Figure 8 XRPD pattern of crystal seed of compound (I) prepared in Example 1; Figure 9 A physical image of crystal form A of compound of formula (I) prepared in Example 2; Figure 10 The DSC curve of the free crystal form A prepared in Example 1; Figure 11 The TGA curve of the free crystal form A prepared in Example 1; Figure 12 The ¹H-NMR spectrum of the free crystal form A prepared in Example 1. Detailed Implementation
[0020] The examples given below are for illustrative purposes only and are not intended to limit the scope of the invention. Unless otherwise specified, conditions in the examples are performed under standard conditions or as recommended by the manufacturer. Reagents or instruments whose manufacturers are not specified are all commercially available products.
[0021] The inventors previously developed an HsClpP agonist with a novel skeleton, the structural formula of which is shown in formula (II):
[0022] (II).
[0023] Example 1: Preparation of crystal seed of compound (I) crystal form A In this embodiment, the above-mentioned compound of formula (II) (preparation method see CN121914112A) is used as raw material to prepare crystal seed of formula (I) compound of crystal form A. The preparation method is as follows: (1) Add 1.1 g of compound (II) and 11 mL of anhydrous acetonitrile to a 50 mL flask, then add Me3N·SO3 (6 eq) and triethylamine TEA (12 eq) sequentially. Stir at 65 °C for 16 hours, then filter at 0 °C. After concentrating the filtrate, add 55 mL of anhydrous ethanol and slurry to obtain 1.1 g of solid product. Dissolve the solid in 11 mL of NaOH (4 eq) aqueous solution and stir to mix. After the system is initially clear, solid precipitates out. Add methanol until the system is clear again. Add 3 mol / L hydrochloric acid dropwise under stirring to adjust the pH to 7, and allow to stand to crystallize. Add 11 mL of dichloromethane to the system for dispersion, filter to collect the solid, dry, and obtain 0.83 g of free crystalline form A. Its structural formula is as follows:
[0024] (III).
[0025] (2) Weigh 40 mg of the free crystal form A obtained in step (1) and add it to a 2 mL glass bottle. Under stirring at 50 °C, add 0.9 mL of acetonitrile / water mixed solvent (90:10, v:v) to the glass bottle to form a suspension. (3) Add 0.07 mL of dilute hydrochloric acid aqueous solution (approximately 1.05 equivalent of the free molar ratio) to the suspension in step (2). After adding, the system remains in suspension state. Stir the resulting suspension at 50°C for 2 hours, then cool it naturally to 25°C, and continue stirring at 25°C for 2 days (until crystals precipitate). The dilute hydrochloric acid aqueous solution is prepared as follows: 0.1 mL of 12M hydrochloric acid is diluted with 0.9 mL of acetonitrile / water mixed solvent (90:10, v:v).
[0026] (4) The product obtained in step (3) was filtered through a 0.45 μm nylon membrane filter and centrifuged at 14,000 rpm. The solid was collected and dried under vacuum at 50 °C for 2 hours to obtain crystal seed of compound (I) A.
[0027] The XRPD pattern of free crystal form A is shown below. Figure 7 Characteristic peaks are shown in Table 1. (From...) Figure 7 As shown in Table 1, the free crystal form A of formula (III) prepared in Example 1 has characteristic diffraction peaks at 2θ of 6.8°, 11.9°, 12.1°, 14.1°, 15.5°, 17.9°, 19.4°, 20.4°, 21.5°, 22.3°, 23.7°, 26.9° and 27.9°, with an error range of ±0.2° for the 2θ values.
[0028] Table 1 Characteristic peaks of free-state crystal form A
[0029] The XRPD pattern of crystal seed A of compound (I) is shown in Figure 1. Figure 8 Characteristic peaks are shown in Table 2. (From...) Figure 1 As shown in Table 2, the crystal seed of compound (I) prepared in Example 1 has characteristic diffraction peaks at 2θ of 6.1°, 7.3°, 11.3°, 12.2°, 13.2°, 16.0°, 16.7°, 20.1°, 22.6°, 24.5°, 25.0°, 25.7° and 30.2°, with an error range of ±0.2° for the 2θ values.
[0030] Table 2 Characteristic peaks of crystal form A of compound (I)
[0031] Example 2: A method for preparing crystal form A of compound (I) includes the following steps: (1) Weigh 600 mg of the free crystal form A prepared in Example 1 and add it to an 8 mL glass bottle. Under stirring at 50 °C, add 4 mL of acetonitrile / water mixed solvent (90:10, v:v) to form a suspension. (2) Add 1.065 mL of dilute hydrochloric acid aqueous solution (approximately 1.05 equivalents of the free molar ratio, prepared in the same manner as in Example 1) to the suspension in step (1). After adding the solution, the system remains in a suspension state. Then add 5 mg of the seed crystals prepared in Example 1 and stir at 50°C for 2 hours. Then cool naturally to 25°C and continue stirring at 25°C for 3 days (until crystals precipitate). (3) The product obtained in step (2) was filtered through a 0.45 μm nylon membrane filter and centrifuged at 14,000 rpm. The solid was collected and dried under vacuum at 50 °C for 2 hours to finally obtain 609 mg of compound (I) crystal form A, which is an off-white solid (see Figure 9 The yield was 95%.
[0032] The structural formula of crystal form A of compound (I) is as follows:
[0033] (I).
[0034] X-ray powder diffraction (XRPD; Bruker D8 Advance; test conditions: Cu / K-Alpha1, 40 kV, 40 mA, 2-40°) was performed on the crystal form A of compound (I) prepared in Example 2 using Cu-Kα radiation. Specific results are shown in Table 3 and... Figure 1 From Table 3 and Figure 1 It can be seen that the crystal form A of compound (I) prepared in Example 2 has characteristic diffraction peaks at 2θ of 6.2°, 7.3°, 11.3°, 12.2°, 13.3°, 16.0°, 16.7°, 20.1°, 22.6°, 24.5°, 25.0°, 25.7° and 30.2°, with the error range of 2θ values being ±0.2°.
[0035] Table 3 Characteristic peaks of crystal form A of compound (I)
[0036] Experimental Example 1: DSC, TGA and hydration state analysis of crystal form A of compound (I) prepared in Example 2 Differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and Karl Fischer moisture determination (KF) were used to analyze the crystal form A of compound (I) prepared in Example 2. The specific results are as follows: (1) The obtained samples were tested using a differential scanning calorimeter (TA Instruments Discovery 2500; test conditions: room temperature - 250℃, 10℃ / min; N2 (50mL / min), and the test results are as follows. Figure 2 As shown. By Figure 2 It can be seen that the crystal form A of compound (I) exhibits both dehydration endothermic peaks and melting endothermic peaks during the heating process. Specifically, a dehydration endothermic peak appears at approximately 108.0 °C, corresponding to an enthalpy of approximately 110 J / g; a melting endothermic peak appears at approximately 214.8 °C, and decomposition occurs during the melting process.
[0037] (2) The obtained samples were tested using a thermogravimetric analyzer (TA Instruments Discovery 5500; test conditions: room temperature - 300℃, 10℃ / min; N2 (25mL / min), the test results are as follows). Figure 3 As shown. By Figure 3 It can be seen that the crystal form A of compound (I) exhibits weight loss behavior during the heating process. Among them, about 3.3% of the mass is lost in the range of about 100℃ to 180℃, indicating that there is a process of crystal water removal in the sample.
[0038] (3) The water content of the obtained sample was tested by Karl Fischer method. The test results showed that the water content of crystal form A of compound (I) was 3.2 wt%, corresponding to 1.0 water molecules.
[0039] Based on the results of DSC, TGA and KF tests, it was determined that the crystal form A of compound (I) is a monohydrate crystal form.
[0040] Experimental Example 2: Chemical composition and purity analysis of crystal form A of compound (I) prepared in Example 2 The chemical composition and purity of the product obtained in Example 2 were analyzed using high-performance liquid chromatography (HPLC), ion chromatography (IC), and ¹H-NMR. The specific results are as follows: (1) HPLC purity analysis The purity of the obtained samples was determined by high-performance liquid chromatography (Agilent 1260 Infinity II Binary Pump; test conditions: 254 nm, 25°C, 1 mL / min; Mobile phase A: 0.1% TFA in water, Mobile phase B: 0.1% TFA in CAN; Diluent: ACN / water (50:50, v:v), Needle wash: ACN / water (50:50, v:v)). The results showed that the chemical purity of crystal form A of compound (I) was 99.7%, indicating that crystal form A of compound (I) prepared in Example 2 has high chemical purity.
[0041] (2) Ion chromatography analysis The chloride ion content in the obtained samples was detected by ion chromatography (Metrohm 940 professional IC; test conditions: 30℃, 0.7 mL / min (anion); Eluent (anion): 3.2 mmol / L Na2CO3 + 1.0 mmol / L NaHCO3 in water; Suppressor solutions: 2% (v / v) H3PO4 in water). The results showed that the molar ratio of compound (I) to hydrochloric acid was 1:1.1. Combined with the XRPD, DSC, TGA, and KF analysis results of crystal form A, it was determined that crystal form A is the hydrochloride salt of compound (I).
[0042] (3)¹H-NMR analysis The structure of the obtained sample was confirmed by ¹H-NMR, and the detection results are as follows: Figure 4 As shown. By Figure 4It can be seen that no obvious residual solvent peaks were detected in the sample, indicating that crystal form A has high purity and no detectable organic solvent residues were introduced during the preparation process.
[0043] Based on the combined HPLC, IC and ¹H-NMR analysis results, it was confirmed that the crystal form A of compound (I) prepared in Example 2 has a clear chemical composition and high chemical purity.
[0044] Experimental Example 3: DSC, TGA and hydration state analysis of free crystal form A prepared in Example 1 The free crystalline form A prepared in Example 1 was analyzed using differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and Karl Fischer moisture determination (KF). The specific results are as follows: (1) The obtained samples were tested using a differential scanning calorimeter (TA Instruments Discovery 2500; test conditions: room temperature - 250℃, 10℃ / min; N2 (50mL / min), and the test results are as follows. Figure 10 As shown. By Figure 10 It can be seen that the dehydration initiation temperature of free crystal form A is 127.8℃, and the dehydration enthalpy is about 130J / g; the melting initiation temperature is 210.9℃, and the sample decomposes during melting.
[0045] (2) The obtained samples were tested using a thermogravimetric analyzer (TA Instruments Discovery 5500; test conditions: room temperature - 300℃, 10℃ / min; N2 (25mL / min), the test results are as follows). Figure 11 As shown. By Figure 11 It can be seen that the free crystalline form A exhibits weight loss behavior during the heating process. Specifically, a mass loss of about 3.6% occurs in the range of approximately 100-160℃, indicating that a process of removing crystalline water exists in the sample.
[0046] (3) The water content of the obtained sample was tested by Karl Fischer method. The test results showed that the water content of free crystal form A was 4.0 wt%, corresponding to 1.1 water molecules.
[0047] Based on the results of DSC, TGA and KF tests, it was determined that the free crystal form A is a monohydrate crystal form.
[0048] Experimental Example 4: Chemical composition and purity analysis of free crystal form A prepared in Example 1 The structure of the obtained free crystalline form A sample was confirmed by ¹H-NMR spectroscopy, and the results are as follows: Figure 12 As shown. By Figure 12It can be seen that no obvious residual solvent peaks were detected in the sample, indicating that the free crystal form A has high purity and that no detectable organic solvent residues were introduced during the preparation process.
[0049] Experimental Example 5: Solid-state stability study of crystal form A of compound of formula (I) prepared in Example 2 To evaluate the solid-state stability of compound (I) crystal form A prepared in Example 2 under different temperature and humidity conditions, it was placed under open conditions of 40℃ / 75% relative humidity (RH) and 25℃ / 60% relative humidity (RH) for one week, respectively. Before and after the stability test, X-ray powder diffraction (XRPD) was used to analyze the crystal form of the samples, and high-performance liquid chromatography (HPLC) was used to detect changes in the chemical purity of the samples. The test results are as follows: (1) Evaluation of crystal form stability Depend on Figure 5 It can be seen that after being placed under conditions of 40℃ / 75%RH and 25℃ / 60%RH for one week, the XRPD pattern of crystal form A of compound (I) did not change significantly, and no new diffraction peaks were observed. The results indicate that crystal form A of compound (I) can maintain its crystal structure stability under the above temperature and humidity conditions.
[0050] (2) Evaluation of chemical stability HPLC analysis showed that after one week under the above conditions, the sample did not exhibit significant degradation, and its chemical purity remained largely unchanged. The results indicate that crystal form A of compound (I) possesses good chemical stability under the aforementioned conditions.
[0051] The results above show that after being placed under open conditions of 40℃ / 75%RH and 25℃ / 60%RH for one week, the crystal form A of compound (I) did not undergo significant crystal form transformation or chemical degradation, exhibiting good solid-state stability.
[0052] Experimental Example 6: Dynamic water vapor adsorption study of crystal form A of compound (I) prepared in Example 2 The water absorption and dehydration behavior of crystal form A of compound (I) was tested at 25°C using the dynamic wet range method (DVS) under the cycling conditions of 40-95-0-95-40%RH. XRPD measurements were performed after the DVS test to determine the crystal form change. The test results are shown in Table 4. Table 4 shows that no significant water adsorption was observed in crystal form A of compound (I) within the 40%RH to 80%RH range, with a water absorption rate of 0%, indicating that this crystal form does not exhibit significant hygroscopicity under normal humidity conditions.
[0053] Table 4. Dynamic water vapor adsorption / desorption test results for crystal form A of compound (I)
[0054] Further XRPD analysis was performed on the samples before and after the DVS test. Figure 6 It can be seen that after dynamic water vapor adsorption testing, the XRPD pattern of crystal form A of compound (I) did not change significantly, and no new diffraction peaks were observed, indicating that crystal form A of compound (I) did not undergo significant crystal form transformation during the moisture absorption process. In addition, the DVS test results showed that crystal form A of compound (I) could maintain its crystalline water state even under low humidity conditions (0%RH), and no significant crystal form change caused by dehydration was observed.
[0055] In summary, the free crystal form A and the compound crystal form A of formula (I) of the present invention have good hygroscopic stability and can maintain a stable crystal structure under different humidity conditions, making them suitable for pharmaceutical formulation and storage development.
[0056] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A free crystalline form of a casein lyase agonist, characterized in that, Its chemical structural formula is shown in formula (Ⅲ): (Ⅲ) The free-state crystal form exhibits characteristic diffraction peaks at 2θ values of 6.8°±0.2°, 11.9°±0.2°, 12.1°±0.2°, 14.1°±0.2°, 15.5°±0.2°, 17.9°±0.2°, 19.4°±0.2°, 20.4°±0.2°, 21.5°±0.2°, 22.3°±0.2°, 23.7°±0.2°, 26.9°±0.2°, and 27.9°±0.2°.
2. The method for preparing the free crystal form according to claim 1, characterized in that, Includes the following steps: Me3N·SO3 and triethylamine were added sequentially to a mixed solution of compound (II) and anhydrous acetonitrile. The mixture was then stirred at 60-70°C for 15-20 hours. After filtration at 0-10°C, the filtrate was concentrated and then slurried with anhydrous ethanol to obtain an intermediate solid. The intermediate solid was dissolved in an aqueous sodium hydroxide solution and methanol was added until the system was completely dissolved. Then, hydrochloric acid was added dropwise under stirring to adjust the pH to 4-7. After crystallization, dichloromethane was added to disperse the slurry. After filtration, the obtained solid was dried to obtain the free crystalline form. Wherein, the equivalent range of Me3N·SO3 is 6-8, the equivalent range of triethylamine is 10-12, and the equivalent range of sodium hydroxide is 3-5; the structural formula of the compound of formula (II) is as follows: (Ⅱ)。 3. A hydrochloride crystal form of a casein lyase agonist, characterized in that, Its chemical composition is C 23 H 23 FN4O5S·HCl·H2O, the structural formula is shown in formula (Ⅰ): (Ⅰ) The hydrochloride crystal form exhibits characteristic diffraction peaks at 2θ values of 6.2°±0.2°, 7.3°±0.2°, 11.3°±0.2°, 12.2°±0.2°, 13.3°±0.2°, 16.0°±0.2°, 16.7°±0.2°, 20.1°±0.2°, 22.6°±0.2°, 24.5°±0.2°, 25.0°±0.2°, 25.7°±0.2°, and 30.2°±0.2°.
4. The method for preparing the hydrochloride crystal form according to claim 3, characterized in that, Includes the following steps: (1) Prepare crystal seed of compound (I) using the free state crystal form described in claim 1; (2) Add the free crystal form of formula (Ⅲ) to the mixed solvent and stir at 40-60℃ to form a suspension; (3) Add hydrochloric acid solution and the crystal seed of compound (I) obtained in step (1) to the suspension in step (2), and then stir at 40-60°C for 1.5-2.5 hours. Then cool to 20-30°C and stir at this temperature until crystals precipitate. (4) The product obtained in step (3) is filtered, centrifuged and the solid is collected. The solid is then dried to obtain the final product.
5. The preparation method according to claim 4, characterized in that, The specific process of step (1) is as follows: S1. The free crystal form described in claim 1 is added to a mixed solvent of acetonitrile and water, and stirred at 40-60°C to form a suspension; S2. Add hydrochloric acid solution to the suspension in step S1, then stir at 40-60°C for 1.5-2.5 hours, then cool to 20-30°C and stir at this temperature until crystals precipitate. S3. Filter the product obtained in step S2, centrifuge and collect the solid, then dry the solid to obtain the final product.
6. The preparation method according to claim 5, characterized in that, The volume ratio of acetonitrile to water in step S1 is 88-92:8-12.
7. The preparation method according to claim 4, characterized in that, The mixed solvent in step (2) is a mixture of organic solvent and water; the volume ratio of the organic solvent to water is 88-92:8-12; and the organic solvent is acetonitrile.
8. The preparation method according to claim 4, characterized in that, The amount of hydrochloric acid solution added in step (3) is 1.0-3.0 equivalents of the molar amount of the free crystal form as described in claim 1.
9. The use of the free crystal form of claim 1 or the hydrochloride crystal form of claim 3 in the preparation of medicaments for the prevention and / or treatment of diseases mediated by HsClpP.
10. A medicament for the prevention and / or treatment of diseases mediated by HsClpP, characterized in that, Includes the free crystal form as described in claim 1 and / or the hydrochloride crystal form as described in claim 3.
Citation Information
Patent Citations
Casein lyase agonist as well as preparation method and application thereof
CN121914112A
